Additional benefit of Eisai's Lenvima determined by German regulator

21 December 2015

German pharma regulator the Federal Joint Committee (G-BA) has confirmed an additional patient-relevant therapeutic benefit for Lenvima (lenvatinib) for the treatment of people with radioactive iodine refractory differentiated thyroid cancer (RAI refractory DTC).

This decision follows the publishing of a benefit assessment report for lenvatinib on October 1, 2015, notes the drug’s developer and marketer, Japanese drug major Eisai (TYO: 4523).

"Eisai is delighted about the favorable G-BA decision which successfully concludes the assessment of the additional benefit of lenvatinib for patients in Germany with RAI refractory DTC. Continued reimbursement in Germany for patients living with this difficult-to-treat cancer remains unaffected," commented Gary Hendler, president and chief executive of Eisai EMEA and president, Eisai Oncology Global Business Unit.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK